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Abstract In order to clarify the pathogenesis and pathophysiol-
ogy of cardiac hypertrophy in carnitine-deficient juvenile visceral 
steatosis (JVS) mice, we performed mRNA differential display 
analysis with total RNA extracted from the ventricles of control 
and JVS mice at 14 days of age. We identified four up-regulated 
genes, two known and two unknown, and a novel down-regulated 
gene. Northern blot analysis with a novel cDNA probe derived 
from the down-regulated gene fragment 8A2 revealed three 
mRNA species of 1.1-, 1.3-, and 2.6-kb. The 1.1- and 1.3-kb 
mRNA species were found only in the heart, and the 2.6-kb 
species was found in the heart, kidney and brain, but not in 
skeletal muscle or liver. The 1.1- and 1.3-kb species were down-
regulated in the ventricles of JVS mice, but not in the auricles, 
and increased to the control level with carnitine treatment. We 
isolated cDNA clones from ventricle RNA, termed CDV-1 
(carnitine deficiency-associated gene expressed in ventricle) and 
from brain RNA, termed CDV-1R (CDV-1-related gene) by 5'-
and 3'-RACE analyses. The entire nucleotide sequence except 
the 5'-terminal 64 bp of CDV-1 cDNA was completely identical 
to the 992 bp sequence from the 3'-end of CDV-1R cDNA. The 
CDV-1 cDNA contained an open reading frame predicting a 
peptide of 107 amino acids, which composed the C-terminal 
portion of CDV-1 R peptide consisting of 414 amino acids. 
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1. Introduction 
Juvenile visceral steatosis (JVS) mice were described in 1988 
by Koizumi et al. [1] as a novel animal model with a Reye-like 
syndrome suffering from fatty liver, hyperammonemia, hypo-
glycemia and growth retardation. We have reported the sup-
pressed expression of the urea cycle enzyme genes in the liver 
of JVS mice to be a mechanism of hyperammonemia [2-6]. In 
addition, the most important finding in JVS mice study was 
that the mice were deficient in carnitine [7] and that all the 
symptoms disappeared after carnitine treatment [8]. The mice 
were defective in renal carnitine transport [9], and the jvs gene 
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causing systemic carnitine deficiency was mapped to chromo-
some 11 [10]. As in the human counterpart , we found typical 
and geniune cardiac hypertrophy in JVS mice recognizable 
from 10 days of age and showed that the gene expression 
pattern in the hypertrophied JVS heart differed from that in 
pressure-loaded models [11,12]. 
To further characterize and define the pathogenesis and 
pathophysiology of the hypertrophy in JVS mice at the mo-
lecular level, we applied m R N A differential display analysis. 
Uenaka et al. [13] carried out a similar analysis on JVS mice 
and reported that carnitine palmitoyltransferase I (CPT-I) 
gene was expressed three to six times higher in the heart of 
JVS mice than in control. They reported that CPT-I gene was 
repressed to the normal level when the mice were treated with 
carnitine. In the present study, we report a novel gene, ex-
pressed as three species of m R N A , two of which were down-
regulated in the ventricles of JVS mice. 
2. Materials and methods 
2.1. Animals 
We used homozygous mutant (jvs/jvs) mice, with heterozygous (+/ 
jvs) mice as the control. Heterozygous mice show no clinical manifes-
tations and no difference in heart weight from homozygous control 
mice (+/+) [11,12]. The homozygous mutant and heterozygous control 
mice were produced as previously described [8,11,12]. In the therapeu-
tic experiment, 5 umol of L-carnitine were administered i.p. to JVS 
mice twice a day from 5 to 14 days after birth. 
2.2. RNA preparation 
Mice at 14 days were used, when JVS mice show significant increase 
in heart weight [12]. Tissues were taken from the mice under pento-
barbital anesthesia (50 mg/kg of body weight). The heart was dis-
sected transversely at the bottom of the auricles. The lower part 
was used as ventricular tissue. Total RNA was extracted as described 
by Chomczynski and Sacchi [14] and treated with DNase I using 
MessageClean kit (GenHunter). 
2.3. Differential display 
Differential display analysis was performed essentially as described 
previously [15,16] with the following modifications [17]. Three kinds 
of 3'-anchored oligo-(dT)15 primers (GT15VG, GT15VA or GT15VC 
in which V represented A, C, or G) were used for reverse transcription 
from total RNA and as the 3'-polymerase chain reaction (PCR) pri-
mer. The 5'-PCR primers were 20 kinds of arbitrary primer (Operon 
Technologies), each composed of 10 mer. The first-strand cDNA was 
amplified by PCR in 10 al of final volume containing 0.1 unit of Taq 
polymerase, 1 nmol of dNTP (25 uM each), 4 pmol of 5'-PCR primer, 
2.5 pmol of 3'-PCR primer, 1 uCi of [a-33P]dCTP, 50 mM KC1, 1.5 
mM MgCl2, 10 mM Tris-HCl, pH 8.3 under the following conditions; 
94°C (3 min), 40°C (5 min), and 72°C (5 min) for the second-strand 
cDNA synthesis, followed by 30 cycles of 95°C (15 s), 40°C (2 min) 
and 72°C (1 min) for the amplification, and 72°C (5 min) for the 
additional final extention. As described previously [16], the labelled 
PCR products were separated by electrophoresis using 6% polyacryl-
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amide gels. The interesting DNA bands were re-amplified with the 
same primers as used in the initial reaction, subcloned into pCR II 
vector using the TA cloning kit (Invitrogen), sequenced with ATaq 
fluorescent dye-primer cycle sequencing kit or Thermo sequenase 
core sequencing kit (both from Amersham) and Texas red-labelled 
primers, and run on the Hitachi model SQ-5500 DNA auto-sequencer. 
We confirmed the cloned cDNA fragments to be derived from differ-
entially expressed ones by Southern blot analysis of the originally 
amplified PCR products using the cloned fragments as a probe. 
2.4. Northern blot analysis 
Total RNA was analyzed by Northern blotting as previously de-
scribed [8,12]. The cloned cDNA fragment 8A2 derived from the 
interesting band, which was down-regulated in the ventricle of JVS 
mice, was labelled with the 3'-anchored oligo-(dT)i5 primer, GT15VA, 
in the presence of [a-32P]dCTP and Klenow fragment of DNA po-
lymerase, and used as a probe. The probe for ß-actin used as an 
internal control was generated by labelling a genomic fragment of 
human ß-actin with [a-32P]dCTP and random prime DNA-labelling 
kit (Amersham). 
2.5. cDNA cloning 
To obtain the upstream nucleotide sequence of the novel gene tran-
script containing the sequence of cDNA fragment 8A2, the 5'-RACE 
analysis was carried out using the 5'-RACE System (Gibco BRL). In 
the first step, a first-strand cDNA was synthesized with total RNA 
prepared from ventricle and brain of control mice using fragment 
8A2-specific primer, 5'-CGCAGGCTTTATTTACTTTG-3', and 
SuperScript II. The first-strand cDNA was purified by using a Glass-
MAX spin cartridge, and then an anchor sequence was added to the 
3' end of the cDNA using terminal transferase and dCTP. In the 
second step, PCR amplification was performed using TaKaRa LA 
PCR kit (Takara Shuzo), a nested fragment 8A2-specific primer, 5'-
GCAATCACATCACATCACAA-3', and an anchor primer provided 
with the 5'-RACE System. The downstream nucleotide sequence of 
the novel gene transcript was confirmed by using the 3'-RACE System 
(Gibco BRL) and fragment 8A2-specific primer, 5'-CCAAATTA-
GAGCAGGAAGTG-3'. The 5'- and 3'-RACE products were sub-
cloned into pCR II vector using the TA cloning kit and sequenced by 
using the Thermo sequenase core sequencing kit and the Hitachi SQ-
5500 DNA auto-sequencer as described above. 
3. Results and discussion 
3.1. Differential display analysis of RNAs expressed in 
ventricles of control and JVS mice at 14 days of age 
identified a novel down-regulated gene in JVS mice 
To identify differentially expressed genes in the hypertro-
phied ventricles of JVS mice, we compared mRNA expression 
Fig. 1. Two down-regulated and a constitutive mRNA species in 
the ventricle of JVS mice were detected by Northern blot analysis 
with cDNA fragment 8A2. Total RNA (15 |ig/lane) isolated from 
the ventricles of control (+/jvs) and JVS (jvs/jvs) mice at 14 days of 
age was analyzed by Northern blot hybridization with probes, 8A2 
and ß-actin, as described in Section 2. 
Fig. 2. Tissue distribution of mRNA species detected by cDNA 
fragment 8A2 in control and JVS mice. Total RNA (15 ug per 
lane) isolated from ventricle, auricle, thigh muscle, liver, kidney, 
and whole brain of control (C) and JVS (J) mice at 14 days of age 
was analyzed by Northern blot hybridization. 
patterns in ventricles of control and JVS mice at 14 days of 
age by differential display analysis. By extracting differentially 
expressed cDNA fragments from the polyacrylamide gels, 
cloning and sequencing them with TA cloning system, and 
confirming the differential expression by Southern blotting 
with cloned cDNA fragment as probes, we found that four 
cDNA species were up-regulated to a higher amount and one 
was down-regulated to a much lower amount in the ventricles 
of JVS mice. Of the up-regulated cDNA species, two were 
found to be derived from known genes: ribosomal protein 
L3, reported to play a role in mRNA binding to the ribosome 
[18], and fibronectin, reported to be highly expressed in pres-
sure-loaded model [19]. The other two were not identified as 
known genes with high sequence homology. We confirmed the 
up-regulated expression of these two novel genes in the ven-
tricles of JVS mice by Northern blot analysis (data not 
shown), and are now cloning them. 
On the other hand, the sequence obtained from the down-
regulated cDNA fragment named as 8A2 (306 bp), containing 
a typical polyadenylation signal, AATAAA [20] at the near 
3'-end, showed no significant homology with any published 
genes. By Northern blot analysis using the cDNA fragment 
8A2 as a probe, we found that three mRNA species, two 
intense bands at 1.1- and 1.3-kb, and a faint band at 2.6-
kb, were expressed in the ventricles of control mice and that 
the 1.1- and 1.3-kb species were much lower in the ventricles 
of JVS mice but that there was no difference in the 2.6-kb 
species (Fig. 1). 
3.2. Unique tissue distribution of the three mRNA species 
derived from the novel gene and the unique suppression 
pattern in carnitine-deficient JVS mice 
As shown in Fig. 2, all these three mRNA species were 
intensely expressed in the auricles of both control and JVS 
mice. There was no difference in intensity of these three bands 
between control and JVS mice. In the ventricles, however, the 
1.1- and 1.3-kb species were much lower in JVS mice than in 
control, although there was no difference in intensity of the 
2.6-kb species between control and JVS mice (Figs. 1 and 2). 
The 2.6-kb species was detected in the kidney and brain, but 
not in skeletal muscle and liver, and there was no difference 
between control and JVS mice. These results suggest that the 
1.1- and 1.3-kb mRNA species were expressed specifically in 
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Fig. 3. Diagrammatic representation of nucleotide structure of CDV-1 (carnitine deficiency-associated gene expressed in ventricle) and CDV-1 R 
(CDV-1 related gene) cDNAs cloned with a down-regulated cDNA fragment 8A2 detected by differential display analysis from ventricles. The 
numbers above and below the column or bar denote nucleotide numbers of each cDNA clone. A down-regulated cDNA fragment 8A2 first 
cloned from differential display analysis is shown by a bar. Shaded columns indicate completely identical nucleotide sequences between CDV-1 
and CDV-1R. The nucleotide sequence of the closed column in CDV-1 differed totally from that of the open column in CDV-1R. Open read-
ing frame is shown as ORF. 
heart and suppressed specifically in ventricles of carnitine-de-
ficient JVS mice. When JVS mice were treated with 5 umol of 
carnitine twice a day from 5 to 14 days of age for 10 days, the 
1.1- and 1.3-kb mRNA species were increased to the level of 
control mice (data not shown). 
3.3. Cloning and sequencing of the novel cDNAs from heart and 
brain 
To identify the three mRNA species derived from the novel 
gene corresponding to the fragment 8A2, we cloned cDNAs 
by 5'- and 3'-RACE methods using total RNA prepared from 
the heart and brain of control mice. A full-length cDNA was 
isolated from the heart. We term this cDNA a carnitine defi-
ciency-associated gene expressed in ventricle (CDV-1). The 
construction is shown in Fig. 3. We could not obtain any 
other clones with a sequence different from the CDV-1 
cDNA. At present we have no information about the struc-
tural differences between 1.1- and 1.3-kb mRNA species. As 
shown in Fig. 3, we have constructed cDNA isolated from the 
brain, which we have termed a CDV-1-related gene (CDV-
1R). Although both full-length nucleotide sequences were an-
alyzed by searching for homologies with the EMBL/GenBank/ 
DDBJ data bases using FASTA, no significant similarities 
with any published genes were found. However, the two 
cDNAs identified in the present study showed part identity 
with four EST clones, three from human and one from mouse, 
T80249 (85.4% in 65-366 of CDV-1 and 87.4% in 1573-1953 
of CDV-1R), N44901 (84.8% in 234-548 of CDV-1 and 1827-
2141 of CDV-1R), N98663 (82.3% in 369-548 of CDV-1 and 
1962-2141 of CDV-1R) and AA170087 (99.5% in 514-702 of 
CDV-1 and 2107-2295 of CDV-1R), respectively. 
The entire nucleotide sequence from 65 to 1056 (992 bp) 
except for the 5'-end of CDV-1 cDNA was completely iden-
tical to the 3'-end nucleotide sequence from 1658 to 2649 of 
CDV-1R cDNA. The 5'-end sequence from 1 to 64 of CDV-1 
cDNA was totally different from the corresponding sequence 
from 1 to 1657 of CDV-1 R cDNA. An open reading frame 
(ORF) in each CDV-1 and CDV-1 R cDNA was predicted 
according to the method of Fickett [21] as shown in Fig. 3. 
The ORF of CDV-1 started from ATG at 215 and ended at 
535 followed by a stop codon, TGA, and in the case of CDV-
1R, from ATG start codon at 887 to a last codon at 2128 
followed by a TGA stop codon. As shown in Figs. 3 and 4, 
the peptide sequence deduced from CDV-1 cDNA sequence 
composed the C-terminal one-fourth of the peptide sequence 
deduced from CDV-1 R cDNA. Interestingly, the nucleotide 
sequence from 65 to 214 in CDV-1 cDNA was the 5'-non-
coding region, but that from 1658 to 1807 of CDV-1R cDNA 
was involved in the coding region, which is located in the 
middle one-eighth portion of the CDV-1R peptide. Both 
CDV-1 and CDV-1 R cDNAs contained a 521-nucleotide 3'-
untranslated region with a typical polyadenylation signal, 
CDV-1R 1 MKRLEEEIKFNSYMVTEKFPKELESKKKELHFLQKVVSEPAMGHSDLLEL 50 
51 ETKVNEVNTEINQLIEKKMMRNEPIEGKLSLYRQQASII SRKKEAKAEEL 100 
101 QETKEKLASLEREVLVKTNQTREFDGTEVLKGDEFKRYVSKLRSKSTVFK 150 
151 KKHQIIAEFKAEFGLLQRTEELLKQRQET1QHQLRTIEEKKGISGYSYTQ 200 
201 EELERVSALKSEVDEMKGRTLDDMSEMVKKLNSLVSEKKSALAPVIKELR 250 
251 QLRQKCQELTQECDEKKAQYDSCAAGLESNRSKLEGEVRGLREECLQEES 300 
CDV-1 1 MIKNLEVELRRATDEMKAYVSSDQUEKRKA1REÛYTKNITEÛE 43 
CDV-1R 301 KYHYTNCMIKNLEVELRRATDEMKAYVSSDQGEXRKAJREUYTKNiTEQE 350 
CDV-1 44 NLGKKLREKQKAVRESHGPMMKQAKMWRDLEOLMECKKÛCFLKÛQSPASI 93 
CDV-1R 351 NLGKKLR£KQKAVRESHGPNMKQAKM*RDLEOLMECKK.ÛCFLKQQSPASI 400 
CDV-1 94 GQVIQEGGEDRLVL 
CDV-1R 401 GQVIQEGGEDRLVL 
107 
414 
Fig. 4. Amino-acid sequences deduced from CDV-1 and CDV-1 R cDNAs. Predicted amino-acid sequences are shown by single-letter code. The 
numbers of amino-acid positions relative to initiating Met are shown. The shaded sequences of CDV-1 and CDV-1R are completely identical. 
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AATAAA [20], 32-37 bases upstream of the poly(A) tail. 
These results together with the unique expression pattern of 
CDV-1 and CDV-1R among tissues in control and JVS mice 
(Fig. 2) strongly suggest that they share exon(s), but that their 
expression is independently regulated by different promoters. 
3.4. Amino-acid sequence of CDV-1 and CDV-1 R peptides 
The peptides deduced from CDV-1 and CDV-1 R genes 
(Fig. 4) showed calculated molecular masses of 12578 and 
48 538 Da, respectively. Both peptides were hydrophilic and 
basic, containing high numbers of Lys, Glu, Gin and Leu. A 
search of protein data bases using BLAST and FASTA indi-
cated that both CDV-1 and CDV-1 R peptides were in a lim-
ited region slightly homologous (up to 20%) to proteins hav-
ing oc-helical coiled-coil structure, such as NUF1, which is a 
potential component of the yeast nucleoskeleton [22], Caeno-
rhabditis elegans myosin heavy chain [23] and Schistosoma 
mansoni paramyosin [24]. The peptide sequences contain so-
called heptads, having hydrophobic amino acids at 'a' and 'd' 
positions and hydrophilic amino acids at other positions. This 
suggests that the peptides may have a coiled-coil structure. It 
is interesting and important to find out the biological function 
and pathological implications of the novel peptides, especially 
of CDV-1, in carnitine deficiency. 
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